India seeks 5 yr patent waiver for Covid diagnostics, therapeutics from WTO

India, Pakistan, South Africa, and five other countries have jointly proposed a five-year global patent waiver for Covid-19 diagnostics and therapeutics, according to a report by The Economic Times (ET). The submission to the World Trade Organization (WTO) was made on behalf of 65 members on Monday. In the submission, the members emphasised the ongoing importance of diagnostics and therapeutics in the comprehensive fight against the pandemic.
The submission aims to address intellectual property barriers, promote production, and enhance accessibility to critical Covid-19 tools. This would go a long way in enabling developing countries to expand and diversify production and increase accessibility without intellectual property (IP) barriers.
During the G20 Summit in India, Commerce and Industry Minister Piyush Goyal had also urged members to conduct timely discussions on the extension of patent waivers regarding the production and supply of Covid-19 diagnostics and therapeutics. Talks on therapeutic and diagnostics were raised by both India and South Africa during the G20 meets, under the purview of this waiver.
The request follows the US’ decision not to take a stance on extending the waiver, which currently applies only to Covid-19 vaccines. According to a report on Bloomberg, US President Biden reportedly stated that the administration needed more information on the matter, making it unlikely for the group to reach a consensus by the December 17 deadline. Moreover, European Union’s 27 members, the UK, Singapore, Switzerland, Japan and South Korea, all have opposed the waiver, claiming that there was not enough evidence to show IP rights were hampering the supply of treatments and tests of Covid-19.

Related Posts

  • Pharma
  • April 30, 2025
  • 98 views
Centre notifies rules for compounding of offences under Drugs & Cosmetics Act

New Delhi:   The union health ministry has notified the Drugs & Cosmetics (Compounding of Offences) Rules 2025 to allow minor offences to be settled by fine or penalties. His is…

  • Pharma
  • April 30, 2025
  • 98 views
US FDA approves first cell-based gene therapy for rare genetic skin disorder

The U.S. Food and Drug Administration approved Abeona Therapeutics’ (ABEO.O), opens new tab gene therapy for a rare skin disorder on Tuesday. The gene therapy, called Zevaskyn, is approved to…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Centre notifies rules for compounding of offences under Drugs & Cosmetics Act

Centre notifies rules for compounding of offences under Drugs & Cosmetics Act

US FDA approves first cell-based gene therapy for rare genetic skin disorder

US FDA approves first cell-based gene therapy for rare genetic skin disorder

Phthalates in plastics linked to 13 per cent of heart disease deaths in 2018 globally, finds study

Phthalates in plastics linked to 13 per cent of heart disease deaths in 2018 globally, finds study

Cargologic receives CEIV Pharma re-certification

Cargologic receives CEIV Pharma re-certification